Skip to main content
Acticor Biotech logo

Acticor Biotech — Investor Relations & Filings

Ticker · ALACT ISIN · FR0012519668 LEI · 969500K433EK1G89EV95 PA Manufacturing
Open in API
Filings indexed 200 across all filing types
Latest filing 2022-09-26 Regulatory Filings
Country FR France
Listing PA ALACT

About Acticor Biotech

https://www.acticor-biotech.com

Acticor Biotech is a clinical-stage biopharmaceutical company that originated as a spin-off from the French National Institute of Health and Medical Research (INSERM). The company is dedicated to developing innovative treatments for thrombotic diseases, with a primary focus on the acute phase of ischemic stroke. Its lead drug candidate, glenzocimab, is a humanized monoclonal antibody fragment designed to target platelet glycoprotein VI (GPVI), a key receptor involved in thrombosis. The therapeutic approach aims to provide an effective anti-thrombotic effect to safely manage stroke patients without increasing the risk of bleeding, a significant complication associated with existing treatments.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
Regulatory Filings Classification · 100% confidence The document is a press release dated September 26, 2022, announcing a clinical trial milestone: the enrollment of the first US patient in the Phase 2/3 study ACTISAVE for glenzocimab. It details the study progress, regulatory interactions (FDA IND, EMA PRIME status), and provides background on the drug and the company. This type of announcement, focusing on operational and clinical trial updates rather than comprehensive financial results (like 10-K or IR) or formal voting results, best fits the category for general corporate or operational news that doesn't fit a more specific financial or governance code. Since it is a specific operational update about a clinical trial milestone, it is not a standard Earnings Release (ER) or Interim Report (IR). It is not a formal regulatory filing like a 10-K or a specific transaction report. Given the options, this is a general corporate announcement regarding clinical progress. It is not a Call Transcript (CT), Director's Dealing (DIRS), or Dividend Notice (DIV). It is most closely related to general corporate news, but none of the codes perfectly capture a clinical trial update press release. However, it is not a formal report itself, nor is it a management discussion (MDA) or investor presentation (IP). It is a specific announcement of an operational event. In the absence of a 'Clinical Trial Update' code, the most appropriate general category for non-financial, non-governance, non-transactional corporate news that is not a formal report announcement is the fallback category, Regulatory Filings (RNS), as press releases often serve as the primary means of disseminating such information to the market, or sometimes it might be considered an Investor Presentation (IP) if it were more strategic, but here it is purely factual operational news. Given the context of financial filings, this is a general corporate announcement. I will classify it as RNS as the best fit for a general, non-financial/non-governance press release that doesn't fit other specific operational codes.
2022-09-26 English
Inside Information / Other news releases
Report Publication Announcement Classification · 99% confidence The document is a press release dated September 23, 2022, announcing the postponement of the release of the '2022 Half-Year Financial Results' from September 29, 2022, to October 27, 2022. This is not the actual financial report (which would be an IR or AR), nor is it a transcript (CT) or a general earnings release (ER) containing the results. Instead, it is an announcement about the timing of a future report's publication. According to the definitions, an announcement regarding the timing or release of company reports falls under 'Report Publication Announcement' (RPA). The document length is short (3078 chars), supporting the idea that it is an announcement rather than the full report.
2022-09-23 English
Informations privilégiées / Autres communiqués
Report Publication Announcement Classification · 99% confidence The document is a press release titled "Acticor Biotech annonce le report de la publication de ses résultats semestriels 2022" (Acticor Biotech announces the postponement of the publication of its 2022 half-year results). It explicitly states that the scheduled release date for the 'résultats semestriels 2022' (half-year results) has been moved from September 29, 2022, to October 27, 2022. This is an announcement about the timing of a financial report, not the report itself. According to Rule 2, if a document announces the publication or timing of a report, it should be classified as a Report Publication Announcement (RPA). The document length (3531 chars) is short, consistent with an announcement rather than a full financial report (like an IR or 10-K).
2022-09-23 French
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social au 31 aout 2022" (Monthly information relating to the total number of voting rights and shares comprising the share capital as of August 31, 2022). It explicitly references Article 223-16 of the AMF General Regulation and provides a table detailing the total number of shares and theoretical/real voting rights as of a specific date (31/08/2022). This type of periodic disclosure regarding the total number of shares and voting rights is a standard regulatory requirement, often related to capital structure changes or mandatory periodic updates. While it is a regulatory announcement, it specifically deals with the composition of capital and voting rights, which is distinct from general regulatory filings (RNS) or share issuance announcements (SHA). However, none of the specific codes perfectly match a 'Monthly Share Capital/Voting Rights Disclosure'. Given the options, this document reports on the current state of capital structure and voting rights, which is a fundamental aspect of corporate governance and share structure reporting. Since it is a mandatory disclosure about the number of shares and voting rights, it is most closely related to Share Issue/Capital Change (SHA) or a general Regulatory Filing (RNS). Because it is a routine monthly update on the *count* of shares/votes, and not an announcement of a specific transaction (like a buyback or new issue), it fits best under the general regulatory disclosure category, RNS, as it is a specific regulatory communication that doesn't fit the other precise categories like DIV, DIRS, or CAP. Alternatively, if we consider the content as a notification of the current share base, SHA might be considered, but SHA usually implies an *action* changing the base. RNS is the safest fallback for mandatory, non-transactional regulatory updates.
2022-09-09 French
Total number of voting rights and capital / Information on the total number of voting rights and the number of shares making up the capital
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Disclosure of the total number of voting rights and shares as of August 31, 2022" and explicitly references French Commercial Code and AMF (Autorité des Marchés Financiers) regulations regarding the disclosure of share capital and voting rights. This type of mandatory periodic disclosure, detailing the total number of shares and voting rights, is a specific regulatory requirement. While it is a regulatory announcement, it is not a general 'RNS' or a report itself (like 10-K or IR). It specifically relates to the structure of ownership and voting power, which is often captured under general corporate actions or specific regulatory filings. Given the options, this disclosure of total voting rights is most closely related to changes in capital structure or major shareholding notifications, but since it is a mandatory, periodic disclosure of the total count, it fits best under the general regulatory filing category (RNS) or potentially a specific capital/share action. However, the content is purely about the total share count and voting rights as of a specific date, which is a common requirement for maintaining transparency on the capital base. Since there is no specific code for 'Total Voting Rights Disclosure', and it is a formal regulatory communication, 'RNS' (Regulatory Filings) serves as the most appropriate general regulatory fallback, although 'SHA' (Share Issue/Capital Change) is related, this is a reporting of the current state, not an announcement of a change event. Given the context of French mandatory disclosure of share capital, RNS is the safest general classification for this type of routine regulatory update.
2022-09-09 English
Total number of voting rights and capital / Information on the total number of voting rights and the number of shares making up the capital
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document explicitly discloses the "total number of voting rights and shares as of July 31, 2022" pursuant to French Commercial Code and AMF regulations. This type of mandatory disclosure, detailing the breakdown of shares and voting rights, is a specific regulatory filing requirement, often related to capital structure updates or general corporate governance disclosures. It is not an Annual Report (10-K), an Earnings Release (ER), or a Dividend Notice (DIV). Since it deals with the fundamental structure of ownership and voting power, and is a specific regulatory announcement that doesn't fit perfectly into the other defined categories (like DIRS, MRQ, or SHA which focus on transactions or changes in holdings), the most appropriate general regulatory category is 'Regulatory Filings' (RNS), as it is a mandatory disclosure required by the financial authority (AMF). However, given the content is purely about the total share count and voting rights, it is a specific type of capital/share information. Comparing it to the definitions, it is closest to a notification about the capital structure, but since it is a routine, periodic disclosure of the total count rather than a transaction (SHA/POS) or a major shareholder change (MRQ), RNS serves as the best fit for this type of routine regulatory update not covered by a more specific code.
2022-08-03 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.